Pharmacy Podcast Network

The Inaugural ViVE 2022 Conference in Miami - The Post Conference Show

Where there is healthcare for people's lives, Pharmacists must be present. Where were all the Pharmacists at ViVE 2022? The very first ViVE conference was absolutely amazing. ViVE created an immersive environment for interactive learning, idea generation and collaboration for the digital health community to come TogetheRx to advance healthcare. ViVE's inaugural event was on March 6-9, 2022, in Miami Beach, Florida. Where were all the #DigitalHealth Pharmacists? The Pharmacy Podcast Network will work with HLTH and ViVE to assure Pharmacists play a greater role in Tennessee at ViVE 2023. Learn more: https://www.viveevent.com/
Learn more about your ad choices. Visit megaphone.fm/adchoices

Defining and Supporting the Professional Role of Pharmacists Associated with Traditional and Complementary Medicine

Dr. Carolina Ung of University of Macau and Dr. Joanna Harnett are conducting a study to obtain pharmacist opinions on their professional role in complementary medicines. The results of this survey will be used to inform key discussion points in a consensus process and a step towards developing an agreed and defined professional role for pharmacists in traditional and complementary medicines while establishing the support required for pharmacists to enact that role effectively. This is a public health matter implicating the quality and safe use of T&CM.  The findings of this international survey contribute to the development of an international consensus regarding:
professional role of pharmacists regarding T&CM
support required to enact the role effectively and safely
More information about the study and a link to the survey can be found here:
https://www.surveymonkey.com/r/Ph_T_CM_US_20220316
 
The study is entirely voluntary and is completed anonymously.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Pennsylvanians Suffer while Pharmacy Middlemen Profit | PBM Reform Podcast Series

Pennsylvanians suffer while pharmacy middlemen profit
By Suzanna Masartis
Pennsylvanians are getting crushed by the costs they face at their neighborhood pharmacy counter. The situation has grown so bad that a shocking one in five Keystone State residents report they are unable to take their medications as prescribed due to the cost burden.[1]
As a lawmaker and an advocate who speaks to patients in Pennsylvania every day with liver disease, diabetes and other chronic conditions, I am convinced more strongly than ever that we need to reform the prescription drug supply chain.
To understand how we got here we need to understand what’s driving increasing costs. A new report found that, in 2020, manufacturers of brand-name and generic medications received only 37 cents of each dollar of the more than $680 billion spent on medications. If you look exclusively at manufacturers of brand-name medications, the drug makers are taking in just under 50 cents on the dollar. So where is the money going? Turns out that it’s little-known middlemen corporations, Pharmacy Benefit Managers (PBMs), that are taking a bigger and bigger share of the pie.[2]
PBMs were created to negotiate with insurers and drug manufacturers and establish which prescription drugs are covered by a health plan. In reality, they demand steep discounts from drug makers off of the original list price as a condition to include those drugs on the approved list of medications – and then keep the savings for themselves. But here's the real rip-off: Patients at the pharmacy counter still face co-insurance charges based on the list price -- not the discounted price insurers actually pay. In other words, PBMs are enriching themselves while hiking prices for the rest of us. {3}
Worse still, PBMs manipulate their powerful market position to reduce the availability of prescription medications by excluding them from formularies. PBMs make their money when they demand exorbitant rebates from drugmakers and charge patients full cost, meaning they prefer to include drugs with higher list prices on their formulary over an equally effective drug with a lower list price. As a result, a number of drugs are excluded from formularies because PBMs can’t make as much money from them. In 2020, the three largest PBMs excluded 846 FDA-approved drugs, denying patients access to more medications than ever before.
This market manipulation has disastrous results for patients. A study published last year found that these practices, called “drug utilization management,” can lead patients to abandon their prescribed medications and delay treatment. Approximately 20% of prescriptions in the U.S. are never filled, according to the study.[4] This outcome is simply unacceptable, and our leaders need to take action.
Congress needs to ensure that any attempt to rein in out-of-pocket prescription drug costs includes taking a close and hard look at PBMs. Doing so would go a long way toward ensuring every patient and healthcare consumer in our state can access and afford to take their medications as prescribed by their doctor.
Suzanna Masartis of Pittsburgh is the CEO of the Community Liver Alliance.
[1]https://www.healthcarevaluehub.org/advocate-resources/publications/pennsylvania-residents-worried-about-high-drug-costs-support-range-government-solutions
[2]https://ecommunications.thinkbrg.com/44/2328/uploads/brg-pharmaceutical-supply-chain-2022.pdf?intIaContactId=24HydQaSTYqd85tTztTDcQ%3d%3d&intExternalSystemId=1
[3] https://www.fiercehealthcare.com/payer/study-drug-utilization-costs-health-industry-93b-a-year-patients-bearing-most-cost
[4] https://www.healthaffairs.org/doi/full/10.1377/hlthaff.2021.00036
Learn more about your ad choices. Visit megaphone.fm/adchoices

Seizure Clusters: A Review of New Drug Delivery Methods and Emerging Therapy Options | PTCE Pharmacy Connect

Educational Objectives
Examine challenges in current treatment options for seizure clusters, including efficacy and safety, and differentiating routes of administration
Highlight considerations in treatment of seizure clusters, including addressing barriers to treatment and providing patient counseling to improve outcomes
Faculty:
Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM 
Professor
Departments of Pharmacotherapy & Outcomes Science and Neurosurgery
Virginia Commonwealth University, Medical College of Virginia
Richmond, Virginia
Neurocritical Care Clinical Pharmacist
Virginia Commonwealth University Health
Richmond, Virginia
Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FCCM, FNCS, MCCM, has the following relevant financial relationships with commercial interests to disclose:
Grant/Research Support: Department of Defense
Consultant: UCB, Chiesi, Marinus, Alexion, Ceribell
Speakers Bureau: UCB, Chiesi
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hour (0.05 CEU) under the ACPE universal activity number 0290-0000-22-129-H01-P. The activity is available for CE credit through March 31, 2023.
This activity is supported by an educational grant from Neurelis Inc.
Gretchen M. Brophy, PharmD, BCPS, FCCP, FCCM, FNCS, MCCM is Professor of Pharmacotherapy & Outcomes Sciences and Neurosurgery at Virginia Commonwealth University (VCU) School of Pharmacy, Medical College of Virginia Campus. She is a Past President of the Neurocritical Care Society. Dr. Brophy’s research interests include neuropharmacotherapy, traumatic brain injury, biomarkers, hemostasis, stroke, and status epilepticus.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Pittsburgh Pharmacy Business Innovators | RxInfluencers

Pittsburgh Headquartered based Pharmacy Podcast Network welcomes 3 Pittsburgh Pharmacy Business Innovators. 
Todd Eury welcomes Dr. Kyle McCormick to an interesting discussion with fellow pharmacy owners Shawn Nairn and Chris Antypas. Payment model changes, PBM Reform, Cost-plus pricing strategies, and some surprise growth announcements --all part of this dynamic conversation. 
Learn more about your ad choices. Visit megaphone.fm/adchoices

Successful Nutritional Supplements Business in Your Pharmacy | Pharmacy Crossroads

Two accomplished professionals share insights into key things to look for, and to do, have a successful nutritional supplement business in your pharmacy. Dennis Song, R.Ph. and owner of Flower Mound Pharmacy in Flower Mound, Texas is doing remarkable things. Critical to his success, he says, is working closely with prescribers and finding ways for nutraceuticals to become part of their prescribing habits. Getting out of the pharmacy and taking at community events is also a key aspect of success. Mike Ewers, CEO of Medella Springs provides an “insider's” view of the way his company decides which products they can produce that meet a need in the consumer market place and how clinical and functional trials help them produce products that deliver on their promise. At the end of the day, Song says there is a need for pharmacists to get more involved in helping people prevent illness.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Novel Non-stimulant ADHD Treatments: A Review for Pharmacists | PTCE Pharmacy Connect

Educational Objectives
Describe the impact of ADHD and new non-stimulant class of ADHD treatments
Highlight the role of the pharmacist in patient counseling, monitoring and medication management in ADHD
Faculty:
Sandy Mullen, PharmD, BCPP
Clinical Pharmacy Specialist - Child and Adolescent Psychiatry 
Department of Pharmacy 
Virginia Commonwealth University (VCU) Health
Richmond, VA
Sandy Mullen, PharmD, BCPP, has no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-127-H01-P. The activity is available for CE credit through March 30, 2023.
This activity is supported by an educational grant from Supernus.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Digital Health with Bakul Patel | Darshan Talks

In this episode of the DarshanTalks Podcast, we have a discussion about Digital Health with Bakul Patel, Director, Digital Health Center of Excellence of US FDA department. He has over 28 years of leadership, business development, marketing, product management, assessing long and short-term needs, establishing objectives, improving organizational performance, and resource management. Expertise in medical device regulations, product development processes, software engineering, embedded systems, wireless communication systems, and robotics and control systems. Masters in Electronics Engineering, MBA in International Business. Six Sigma, Black-belt certified. With all the bucket of knowledge of digital health, the conversation started off with FDA going through massive changes currently. He explains his area of work in the digital health technology sphere and leading digital health with no jurisdiction boundaries, as this sector is wide in nature, and he further explains how it's always been fun to work in such an atmosphere. When it comes down to FDA there are portions of that spectrum of digital health as it may be general wellness. According to the expert, digital health is a spectrum, a continuum, a journey for an individual and purview under FDA's jurisdiction. The focus of the conversation was on the department that the expert works and the people who don't know much about can reach out to the department for advice, suggestions, reviews or portions of review depending on the products that come to different parts of the agency. There are some policy challenges, he emphasised on FDA needs to start evolving that their agency have been actively working on with other parts of the agency. Recent guidance on digital health tech in clinical trials was launched by his department and he described all the related information and implications in this podcast.
----
Disclaimers:
1. This discussion is merely an oral discussion and should not be relied upon solely on its own to support any conclusion of law or fact.
2. The discussion does not and should not reflect any individual products status as safe, efficacious, adulterated, or misbranded or meeting or not meeting expectations at a local, state, federal, or international agency or organization.
3. The discussion should not be construed to be complete advice that is right for you and may not necessarily represent a specific product.
4. This discussion is provided for general educational purposes and should not be construed as legal advice, regulatory advice, or medical advice.
5. This does not create an attorney-client relationship.
Learn more about your ad choices. Visit megaphone.fm/adchoices

An Insider Discusses How Government Affairs Work Affects Your Pharmacy | Pharmacy Crossroads

If you have ever wondered what government affairs executives do and how they affect the practice of pharmacy then you’ll want to spend 35 minutes listening to this episode. Mark Kinney, a pharmacist, has more spent more than 30 years meeting with elected officials and other influential officials to help them better understand the complex and important role pharmacy owners play in our society. And, as you’ll learn in this podcast, government affairs work goes far beyond PBM and DIR fee battles.  
 
Learn more about your ad choices. Visit megaphone.fm/adchoices

Clinical Decision Support Software: A Key Tool for Optimizing Population Health Level Pharmacogenomics Programs | PGx For Pharmacist

Episode Description:
On this episode, Dr. Jeffrey Shaman, Chief Science Officer at Coriell Life Sciences, and I discuss the importance of population health level pharmacogenomics versus one time pharmacogenomics tests and how clinical decision support software that integrates pharmacogenomics data into patients’ medication therapy management is a key tool to optimize population health level pharmacogenomics programs.
References:
1. Real-World Impact of a Pharmacogenomics-Enriched Comprehensive Medication Management Program https://www.mdpi.com/2075-4426/12/3/421
2. Idiopathic Symptoms Resolved by Pharmacogenomics-Enriched Comprehensive Medication Management: A Case Report https://www.cureus.com/articles/81096-idiopathic-symptoms-resolved-by-pharmacogenomics-enriched-comprehensive-medication-management-a-case-report
3. Consequences of CYP2D6 Copy-Number Variation for Pharmacogenomics in Psychiatry https://www.coriell.com/resources/consequences-of-cyp2d6-copy-number-variation-for-pharmacogenomics-in-psychiatry/
4. The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978656/
5. ASP Establishes March 24th as National Adverse Drug Event Awareness Day https://www.stopadr.org/blog/asp-establishes-march-24-as-national-adverse-drug-event-awareness-day-launches-awareness-campaign
Guest’s Bio:
Jeffrey A. Shaman, PhD, MS, is the Chief Science Officer at Coriell Life Sciences (CLS), an international leader in precision medicine. Leveraging extensive experience in genetics and pharmacology, he is a leading expert in the rapidly evolving field of pharmacogenomics (PGx), the study of how an individual’s DNA impacts his or her response to medication. Most importantly, Dr. Shaman plays a critical role in bridging the gap between genetic science and clinical application. This includes translating decades of cutting-edge genetic research into actionable insights on the safest and most effective medications for individuals based on their unique DNA and dozens of other factors.
Driven to advance public health, Dr. Shaman is focused on enabling the delivery of personalized medicine at scale and empowering the most precise medical care worldwide. He consults with large employers, public and private payer organizations, healthcare systems, academic institutions, and laboratories around the globe, advising them on how to eliminate trial-and-error prescribing, improve population health, and control rising healthcare costs
Dr. Shaman is dedicated to setting the industry standard for PGx and pioneering new advancements in the field. Along with his team, he actively researches and presents findings in top peer-reviewed journals and at leading industry events. He is an active member of the Clinical Pharmacogenetics Implementation Consortium (CPIC), Standardizing Laboratory Practices in Pharmacogenomics (STRIPE) Collaborative Community, Personalized Medicine Coalition (PMC), Pharmacogenomics Global Research Network (PGRN), and other organizations.
Dr. Shaman holds a doctoral degree from The Johns Hopkins University School of Medicine in Pharmacology and Molecular Sciences, where his research centered on DNA, epigenetics, and nuclear structure and function. He earned his Master of Science degree from The University of Medicine and Dentistry of New Jersey in Cell & Developmental Biology. Dr. Shaman held a faculty position at the University of Hawai‘i Institute of Biogenesis Research before serving a fellowship at Harvard Medical School and implementing a translational research program at Beth Israel Deaconess Medical Center and the Bedford Stem Cell Research Foundation.
Learn more about your ad choices. Visit megaphone.fm/adchoices

DIRs, Clawbacks, & Opacity: CMS’ Drug Pricing Debacle | The PUTTcast

The unethical business practices by PBMs when it comes to our nation's seniors run the gamut from unreasonable fees and metrics to underhanded pricing models and what could easily be considered larceny against taxpayers. Join PUTTcast co-hosts Monique Whitney and Lauren Young, with special guests Tim Hamrick and Greg Reybold of APCI to discuss the results of their explosive 3Axis study, possible outcomes of the proposed CMS rule change, and why moving prescription drug plans to a NADAC pricing model is so important for lowering costs and increasing transparency.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Therapeutic Alternatives, Reimbursements, and the Economic Impact of ActiveRADAR | PBM Reform Podcast Series

Dave Teckman, Executive Chairman at ActiveRADAR joins the PBM Reform Podcast series about the impact of therapeutic interchange technologies on PBM pricing & the powerful data at the pharmacist's fingertips with ActiveRADAR.
Through rigorous clinical evaluation of all drugs in over 112 therapeutic categories, ActiveRADAR first establishes which drugs are clinically equivalent and therefore therapeutic alternatives to one another. This creates our Clinical Catalog of over 26,000+ therapeutically equivalent “perfect pairs”. Then ActiveRADAR determines the economic value using plan specific data to value each drug within its respective therapeutic class and sets pricing and reimbursement accordingly. This type of program has historically been called “reference pricing”, however ActiveRADAR takes it a step further by establishing both THE CLINICAL AND ECONOMIC VALUE OF EACH AND EVERY DRUG IN EACH THERAPEUTIC DRUG CLASS.
About ActiveRadar:
ActiveRADAR, formerly RxTE Health, is a healthcare analytics and patient education company providing unique data-driven, cost-saving customized prescription options. Using proprietary technology, ActiveRADAR identifies the lowest cost prescription options.
Learn more about your ad choices. Visit megaphone.fm/adchoices

PDS Super Conference 2022 Post-Show | Part TWO

PDS is 100% focused on equipping independent pharmacy owners with the skills they need to make their life better and their business more valuable. Each year, PDS hosts the leading independent pharmacy business conference, The PDS Super-Conference has thousands of pharmacy owners attend to discover what’s hot and what’s working right now in the industry. The Pharmacy Podcast Network was a proud media partner of the PDS 2022 Event.
Special Guests:
Jennifer Diehl, CPA, CPC, DBA
PDS | Business Coach
Drew Hegi, MBA
Loan Officer Pharmacy Owner dhegi@ffb1.com
Jon Allman and Mike Wilhoit
Mac's Pharmacy | Hometown Pharmacies in Tennessee
Learn more about your ad choices. Visit megaphone.fm/adchoices

The Least of Us in Dreamland | PAIN POD

What do Mexico, drugs, society, the Bible, and whiskey have in common? Join us on this episode of the PAIN POD, as Mark “Pain Guy” Garofoli chats with Sam Quinones, author of “Dreamland” and “The Least of Us”, with the later having just released in October 2021. It’s often hard to see the forest within the trees, but Sam clears the fog for all of us to whittle it down on how to provide patient care for those in pain and/or with addiction. Come one, come all, to the Pain Pod!!!
Sam Quinones
https://samquinones.com/
Drug/Overdose Trends
https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates
https://www.iqvia.com/insights/the-iqvia-institute/reports/prescription-opioid-trends-in-the-united-states
FreeCE Substances of Abuse Specialty Pharmacist (SASP) Certificate
https://www.freece.com/Programs/SeriesCertification/ab66a419-b5e5-458b-9494-0acb6af1be92
CDC Opioid Guideline Updated Draft for Public Comment
https://www.regulations.gov/docket/CDC-2022-0024/document
Learn more about your ad choices. Visit megaphone.fm/adchoices

What Will Cost Plus Drugs mean for Your Pharmacy Long Term? | RMS CLIMB

What will Cost Plus Drugs mean for your pharmacy? What New Challenges does it bring and what opportunities does it present? And then what do you do about it? Join us for a discussion on the impact of of Cost Plus Drugs on retail pharmacy with Hartig Drug CEO Charlie Hartig.
Learn more about your ad choices. Visit megaphone.fm/adchoices

Reverse Your Reliance on 503Bs for Compounded Sterile Products | The Future of Pharmacy Podcast

Learn how the University of Maryland Medical Center reversed its reliance on 503B vendors through an IV robotics insourcing program for compounded sterile products (CSPs). The result is a strategic services operation delivering advanced CSP services across its organization, resulting in improved safety, increased efficiencies, and significant cost savings
Learn more about your ad choices. Visit megaphone.fm/adchoices

PDS Super Conference 2022 Post-Show | Part ONE

PDS is 100% focused on equipping independent pharmacy owners with the skills they need to make their life better and their business more valuable. Each year, PDS hosts the leading independent pharmacy business conference, The PDS Super-Conference has thousands of pharmacy owners attend to discover what’s hot and what’s working right now in the industry. The Pharmacy Podcast Network was a proud media partner of the PDS 2022 Event.
In this episode:
Marci Strauss PharmD, Tom Wheelwright, CPA, Nina Klemm, and Patrick Lott
Learn more about your ad choices. Visit megaphone.fm/adchoices

SBA Financing for Pharmacies | Pharmacy Insiders

Drew Hegi and Bo Garmon
SBA Financing for Pharmacies
Why is FFB Qualified?
Is SBA the best option?
What types of loans are offered?
Can an existing loan be refinanced?
What information do you ask for?
What make a bankable loan?
How do you valuate a pharmacy?
What’s the difference between valuation and appraisal?
Learn more about your ad choices. Visit megaphone.fm/adchoices

Solidarity…The Only Way Forward – Nurses and LTC Pharmacies | Integra X-Files

Dr. Ernest Grant, president of the American Nurses Association, joins co-hosts Frances 
Nahas and Jim McDonald to discuss the role and circumstances of nursing at long-term care 
facilities – on-going staffing shortages, maintaining mental well-being, and how nurses’ deep 
commitment to caring for patients remains key. 
 
Listen in as they discuss ways LTC pharmacies and nursing can work together to improve 
communication and most importantly, patient care. 
Learn more about your ad choices. Visit megaphone.fm/adchoices

Linking Sex Therapy to Pharmacy with Lindsey Walden | Sex PharmD

I am a licensed professional counselor, and a certified sex therapist. I have spent the last 15 years in private practice helping couples and individuals with all types of relationship, communication, and sexual struggles.
Over the last few years I have started offering coaching and consulting services and transitioning to more of an online model but I do still have a small private practice that I will probably always keep going just because I love it.
I work with all elements of sexual functioning from arousal and desire struggles to orgasm problems to helping my clients maintain healthy sexual practices throughout their life cycle. 
In addition I focus a lot on individuals that identify as part of the LGBT community and make it a safe place for them to discuss things that may be on their mind.
I can be found all over social media, and the following link will give you access to everywhere you can find me https://www.lindsaywalden.com/connect-with-me
If you are needing to send me a direct email you can reach me lindsay@lindsaywalden.com or contact my office 314-485-9189.
Learn more about your ad choices. Visit megaphone.fm/adchoices